share_log

Intensity Therapeutics Signs Collaboration Agreement With The Swiss Group For Clinical Cancer Research SAKK To Conduct Phase 2 Breast Cancer Trial In Europe For INT230-6

Benzinga ·  May 10 20:04
Intensity Therapeutics Signs Collaboration Agreement With The Swiss Group For Clinical Cancer Research SAKK To Conduct Phase 2 Breast Cancer Trial In Europe For INT230-6
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment